BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DCF research report →
Price Chart
About the company
The BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc. operates as a closed-end investment vehicle. Its main objective is to generate substantial current income through investments in credit instruments and other financial assets.
- IPO
- 2017
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on DCF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $138.61M
- P/E
- 6.60
- PEG
- 0.07
- P/S
- 9.76
- P/B
- 1.00
- EV/EBITDA
- 2.09
- Div Yield
- 4.55%
- Gross Margin
- 36.65%
- Op Margin
- -115.28%
- Net Margin
- 148.32%
- ROE
- 16.09%
- ROIC
- -9.93%
Latest fiscal year · YoY change
- Revenue
- $14.20M-0.2%
- Gross Profit
- $5.20M-58.7%
- Op Income
- $-16,369,223
- Net Income
- $21.06M+53.6%
- EPS
- $1.40+53.8%
- OCF Growth
- -67.1%
- FCF Growth
- -67.1%
- 52W High
- $9.24
- 52W Low
- $9.24
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.74
- RSI (14)
- 57
- Avg Volume
- 0
No earnings-call transcripts are available for DCF yet.
- Free Float
- 0.0%
- Shares Outstanding
- 15.00M
- Float Shares
- 0
of shares held by institutions
32 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cetera Advisors LLC | 125.10K | ▲ 125.10K |
| Raymond James & Associates | 63.80K | ▼ 15.33K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 1, 23 | Mannan Bushra | other | 0 |
| Aug 1, 23 | Papadoulis Irene | other | 0 |
| Jul 24, 23 | Jiang Ping | other | 0 |
| Dec 28, 22 | Skapyak Bradley J | buy | 1,414 |
| Mar 31, 22 | Martella Joseph | other | 0 |
| Mar 31, 22 | Goldstein Daniel | other | 0 |
| Dec 6, 21 | Pomeroy Robert J. | other | 0 |
| Sep 15, 21 | Miller John Randolph | other | 0 |
| Sep 15, 21 | Larsson Eric | other | 0 |
| Oct 27, 17 | BNY Mellon Investment Adviser, Inc. | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DCF coverage
Recent articles, reports, and earnings notes.
No research on DCF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DCF report →Is HCA Undervalued? DCF Says Worth $785
gurufocus.com · Aug 18
MRSH DCF Analysis: Intrinsic Value $187 vs Price $184
gurufocus.com · Aug 18
CMI DCF Analysis: Intrinsic Value $267 vs Price $641
gurufocus.com · Aug 18
Is ROK Overvalued? DCF Says Worth $161
gurufocus.com · Aug 12
Is PYPL Undervalued? DCF Says Worth $105
gurufocus.com · Aug 12
LHX DCF Analysis: Intrinsic Value $186 vs Price $285
gurufocus.com · Aug 5
Is APH Overvalued? DCF Says Worth $87
gurufocus.com · Jul 20
Is FAST Overvalued? DCF Says Worth $19
gurufocus.com · Jul 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.